Participating Faculty: Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

September 16, 2015
Supplements and Featured Publications, Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin, Volume 21, Issue 11 Suppl

This study and publication were sponsored by Relypsa, Inc.

Faculty

This supplement to The American Journal of Managed Care describes a study that examined reninangiotensin- aldosterone system (RAAS) inhibitor dose levels in a US patient population, investigated the impact of hyperkalemia on RAAS inhibitor dose, and evaluated the association between dose levels and clinical outcomes. The results show that relatively few patients were prescribed maximum doses of RAAS inhibitors, and dose and usage declined following hyperkalemia. Patients on submaximum doses or who discontinued RAAS inhibitors had worse outcomes than patients on maximum doses.Murray Epstein, MD

Professor of Medicine

Division of Nephrology and Hypertension

University of Miami Miller School of Medicine

Miami, Florida

Medical Investigator

South Florida VA Research and Education Foundation

VA Medical Center

Miami, Florida

Susan E. Funk, MBA

Senior Vice President of Data Analytics

Strategic Health Resources

La Cañada, California

John Knispel, MD

Regional Medical Director, Florida

Humana Inc

West Palm Beach, Florida

Karen J. McGaughey, PhD

Associate Professor

Department of Statistics

California Polytechnic State University

San Luis Obispo, California

Nina Oestreicher, PhD

Executive Director

Health Economics and Outcomes Research

Relypsa, Inc

Redwood City, California

Assistant Clinical Professor

University of California, San Francisco

Department of Clinical Pharmacy

San Francisco, California

Nancy L. Reaven, MA

President

Strategic Health Resources

La Cañada, California

Faculty Disclosures

These faculty report relationships with the following organizations:

Murray Epstein, MD

Consultant or paid advisory board: Bayer; OPKO Health; Relypsa, Inc

Lecture fees/meeting conference attendance: Relypsa, Inc

Susan E. Funk, MBA

Consultant/receipt of payment for involvement in preparation of this manuscript: Relypsa, Inc; Strategic Health Resources

John Knispel, MD

Consultant/receipt of payment for involvement in preparation of this manuscript: Relypsa, Inc

Karen J. McGaughey, PhD

Consultant:

Relypsa, Inc; Strategic Health Resources

Nina Oestreicher, PhD

Employment/stock ownership: Relypsa, Inc

Nancy L. Reaven, MA

Consultant: Relypsa, Inc; Strategic Health Resources

Stock ownership: Relypsa, Inc

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.